Literature DB >> 2233123

Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality.

P Noel1, S Nelson, R Bokulic, G Bagby, H Lippton, G Lipscomb, W Summer.   

Abstract

Tumor necrosis factor, a mononuclear phagocyte-derived peptide produced in response to lipopolysaccharide, has been shown to mediate certain aspects of septic shock and multiple organ failure resulting from gram-negative septicemia. In the present investigation, pretreatment of animals with pentoxifylline inhibited lipopolysaccharide-induced serum tumor necrosis factor in a dose-dependent fashion. Pentoxifylline prevented the sequestration of neutrophils seen in animals given intravenous lipopolysaccharide. Furthermore, pentoxifylline protected animals from the lethal effects of an intravenous challenge with lipopolysaccharide. These data indicate that pentoxifylline inhibits lipopolysaccharide-induced tumor necrosis factor and may be an effective agent in mitigating the lethal consequences of sepsis and other disease processes mediated by this cytokine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233123     DOI: 10.1016/0024-3205(90)90474-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin.

Authors:  K Irie; E Fujii; H Ishida; K Wada; T Suganuma; T Nishikori; T Yoshioka; T Muraki
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock.

Authors:  T Staudinger; E Presterl; W Graninger; G J Locker; S Knapp; K Laczika; G Klappacher; B Stoiser; A Wagner; P Tesinsky; H Kordova; M Frass
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 3.  Diagnostic work-up of a peroxisomal patient.

Authors:  J G Leroy; M Espeel; J F Gadisseux; H Mandel; M Martinez; B T Poll-The; R J Wanders; F Roels
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Pentoxifylline inhibits superantigen-induced toxic shock and cytokine release.

Authors:  T Krakauer; B G Stiles
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

5.  Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans.

Authors:  K Miller; A Louie; A L Baltch; R P Smith; P J Davis; M A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 6.  Adrenomyeloneuropathy as a cause of primary adrenal insufficiency and spastic paraparesis.

Authors:  Monika Spurek; Regina Taylor-Gjevre; Stan Van Uum; Hasnain M Khandwala
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

7.  Pentoxifylline pretreatment fails to block the acute-phase response to Escherichia coli endotoxin in dwarf goats.

Authors:  C T Van Duin; T Wensing; A S Van Miert
Journal:  Vet Res Commun       Date:  1995       Impact factor: 2.459

8.  Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity.

Authors:  J Semmler; U Gebert; T Eisenhut; J Moeller; M M Schönharting; A Alléra; S Endres
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

9.  Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin.

Authors:  P Villa; G Sartor; M Angelini; M Sironi; M Conni; P Gnocchi; A M Isetta; G Grau; W Buurman; L J van Tits
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

10.  Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.

Authors:  G W Sullivan; H T Carper; G L Mandell
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.